ADC Development Services Targeting CD352

The signaling lymphocyte activation molecules (SLAM) family of surface proteins represents a group of potential targets for immunotherapy in multiple myeloma (MM). Creative Biolabs provides antibody-drug conjugate (ADC) development services for multiple tumors. We have the capacity of producing ADCs in either research quantities or in large scale for industrial applications. Now, we provide a comprehensive set of anti-CD352 (SLAMF6) ADC development services for our global clients. Besides, the off-the-shelf Anti-CD352 ADC Products are also available for you.

Introduction of CD352

CD352, also known as SLAMF 6, is a type 1 membrane protein in the SLAM family of immunoreceptors. All SLAM family receptor members have the same structure, characterized by an extracellular domain containing an immunoglobulin (Ig) variable-like domain and a C2-like domain, a transmembrane domain, and a cytoplasmic domain containing one or more immunoreceptor tyrosine-based switch motifs (ITSMs). CD352 is expressed on normal natural killer (NK) cells, T cells and B lymphocytes and signals through the ITSM-SAP pathway. CD352 signaling promotes Th1 responses by T cells and leads to proliferation and IFNγ production.

Fig.1 SLAM family member structure.

CD352 is a tumor antigen broadly expressed on B-cell cancers including MM, chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL), while exhibiting low expression on normal white blood cells. The uniform and strong expression in all stages of MM, even the relapse refractory disease, makes certain SLAM family proteins (CS1, CD48, CD352 and CD229) suitable targets for different immunotherapies such as monoclonal antibodies (mAbs), bispecific antibodies, immunoconjugates, cytotoxic T cells, and CAR T cells.

Fig.2 Different types of SLAM-specific immunotherapies. (Radhakrishnan, 2017)

Anti-CD352 ADC in Multiple Myeloma Therapy

CD352 is a newly validated MM tumor antigen and the novel ADC SGN-CD352A shows potent antitumor activity against cell line models of MM at clinically relevant doses. In detail, SGN-CD352A is a humanized anti-CD352 engineered cysteine mAb to which two molecules of pyrrolobenzodiazepine (PBD) dimer, a potent DNA damaging cytotoxic drug, have been conjugated. Upon binding CD352 at the MM cell surface, SGN-CD352A undergoes rapid clathrin-dependent endocytosis and traffics to lysosomal vesicles. PBD dimers released from SGN-CD352A in lysosomes induce a dose dependent DNA damage signaling response in MM cells, activating ATM and ATR kinases, and caspase 3/7 dependent apoptotic cell death results within 48 hours.

What Can We Do for You?

At Creative Biolabs, mAbs specific for human CD352 can be generated through various aproaches according to the client’s specific demands, and potential antibodies be selected based on their affinity, endocytic internalization rate, and tumor cell cytotoxic activity as an ADC component. Creative Biolabs is also capable of providing anti-CD352 engineered cysteine antibody, which will be further stably linked to a highly potent toxin via site-specific conjugation technology. Moreover, Creative Biolabs offers a whole suite of technique platform/services needed for ADC development, including but not limited to the following:

ADC Development Services Targeting CD352

Equipped with state-of-the-art research and manufacturing facilities, Creative Biolabs is dedicated to helping our clients design and prepare highly customized ADC . If you are interested in our anti-CD352 ADC development services, please feel free to contact us for more information.

Reference